---
title: "P/E Ratio Insights for Gilead Sciences"
description: "Gilead Sciences Inc. (NASDAQ:GILD) stock is currently priced at $147.00, reflecting a 1.31% decrease. Despite this, the stock has risen by 4.93% over the past month and 28.42% over the past year. The "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277254163.md"
published_at: "2026-02-27T22:00:36.000Z"
---

# P/E Ratio Insights for Gilead Sciences

> Gilead Sciences Inc. (NASDAQ:GILD) stock is currently priced at $147.00, reflecting a 1.31% decrease. Despite this, the stock has risen by 4.93% over the past month and 28.42% over the past year. The company's P/E ratio is lower than the Biotechnology industry's average of 79.25, suggesting potential undervaluation. However, a low P/E may also indicate weak growth prospects. Investors should consider multiple financial metrics and qualitative factors for a comprehensive analysis before making investment decisions.

In the current market session, **Gilead Sciences Inc. (NASDAQ:GILD)** stock price is at $147.00, after a **1.31%** decrease. However, over the past month, the company's stock increased by **4.93%**, and in the past year, by **28.42%**. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.

![Past Year Chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772229633_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

### Evaluating Gilead Sciences P/E in Comparison to Its Peers

The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued.

Gilead Sciences has a lower P/E than the aggregate P/E of **79.25** of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued.

![Guage](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772229633_1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

### Related Stocks

- [GILD.US - Gilead Sciences](https://longbridge.com/en/quote/GILD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 吉利德科学｜8-K：2025 财年 Q4 营收 79.25 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275510281.md) |
| Puma 生物技术｜10-K：2025 财年营收 2.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/277101995.md) |
| 是时候抄底了？奥本海默上调甲骨文评级：大跌之后即是买入机会 | 甲骨文年初至今跌超 25%，奥本海默将评级从 “与大盘持平” 上调至 “跑赢大盘”，设 185 美元目标价。分析师指出，自 9 月市盈率已下降一半以上，风险回报比极为有利。伯恩斯坦压力测试显示，即便 AI 业务归零，核心业务仍支撑 137  | [Link](https://longbridge.com/en/news/276900810.md) |
| 那些压垮魅族手机的 “最后稻草” | 魅族手机经历多次战略调整后，面临重大危机。尽管 CMO 曾宣布魅族 23 将于年中发布，但项目已于 2 月中旬停摆，手机业务预计于 2026 年 3 月退市。魅族品牌可能继续在吉利体系内运营。随着市场竞争加剧和成本上升，中小手机厂商生存空间 | [Link](https://longbridge.com/en/news/276998913.md) |
| Trump Media & Tech - CW28｜8-K：2025 财年营收 3.7 百万美元 |  | [Link](https://longbridge.com/en/news/277254798.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.